These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 27251370)
1. The mechanisms of delayed onset type adverse reactions to oseltamivir. Hama R Infect Dis (Lond); 2016 Sep; 48(9):651-60. PubMed ID: 27251370 [TBL] [Abstract][Full Text] [Related]
2. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114 [TBL] [Abstract][Full Text] [Related]
3. Cutting Edge: Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. Moore ML; Chi MH; Zhou W; Goleniewska K; O'Neal JF; Higginbotham JN; Peebles RS J Immunol; 2007 Mar; 178(5):2651-4. PubMed ID: 17312105 [TBL] [Abstract][Full Text] [Related]
5. A part-randomized study of intravenous oseltamivir in adolescents and adults. Várkonyi I; Chappey C; Giraudon M; Burleigh L Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1181-8. PubMed ID: 25678009 [TBL] [Abstract][Full Text] [Related]
6. Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Recomm Rep; 1999 Dec; 48(RR-14):1-9. PubMed ID: 10632443 [TBL] [Abstract][Full Text] [Related]
7. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Hama R; Bennett CL Acta Neurol Scand; 2017 Feb; 135(2):148-160. PubMed ID: 27364959 [TBL] [Abstract][Full Text] [Related]
8. The effects of neuraminidase inhibitors on the release of oseltamivir-sensitive and oseltamivir-resistant influenza viruses from primary cultures of human tracheal epithelium. Yamaya M; Nadine L; Kubo H; Saito K; Saito R; Nishimura H J Med Virol; 2015 Jan; 87(1):25-34. PubMed ID: 24838828 [TBL] [Abstract][Full Text] [Related]
9. Electropharmacological characterization of microminipigs as a laboratory animal using anti-influenza virus drug oseltamivir. Lubna NJ; Nakamura Y; Hagiwara-Nagasawa M; Goto A; Chiba K; Kitta K; Izumi-Nakaseko H; Ando K; Naito AT; Akie Y; Sugiyama A J Toxicol Sci; 2018; 43(8):507-512. PubMed ID: 30078836 [TBL] [Abstract][Full Text] [Related]
10. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Hurt AC; Lowther S; Middleton D; Barr IG Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies. Muñoz FM; Anderson EJ; Deville JG; Clinch B; Kamal MA Int J Clin Pharmacol Ther; 2015 Jul; 53(7):531-40. PubMed ID: 26042486 [TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of oseltamivir at standard and high dosages. Dutkowski R; Smith JR; Davies BE Int J Antimicrob Agents; 2010 May; 35(5):461-7. PubMed ID: 20189775 [TBL] [Abstract][Full Text] [Related]
14. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. Lam H; Jeffery J; Sitar DS; Aoki FY Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. Davies BE J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii5-ii10. PubMed ID: 20215135 [TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968 [TBL] [Abstract][Full Text] [Related]
17. Coadministration of Hedera helix L. Extract Enabled Mice to Overcome Insufficient Protection against Influenza A/PR/8 Virus Infection under Suboptimal Treatment with Oseltamivir. Hong EH; Song JH; Shim A; Lee BR; Kwon BE; Song HH; Kim YJ; Chang SY; Jeong HG; Kim JG; Seo SU; Kim H; Kwon Y; Ko HJ PLoS One; 2015; 10(6):e0131089. PubMed ID: 26098681 [TBL] [Abstract][Full Text] [Related]
18. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Ikematsu H; Kawai N Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296 [TBL] [Abstract][Full Text] [Related]
19. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Nakamura K; Schwartz BS; Lindegårdh N; Keh C; Guglielmo BJ Clin Infect Dis; 2010 Apr; 50(7):e47-9. PubMed ID: 20192728 [TBL] [Abstract][Full Text] [Related]
20. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Takahashi E; Kataoka K; Fujii K; Chida J; Mizuno D; Fukui M; Hiro-O Ito ; Fujihashi K; Kido H Microbes Infect; 2010 Sep; 12(10):778-83. PubMed ID: 20452454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]